QNCX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 15:56):

Stats
Today's Volume	95 689.00
Average Volume	70 732.00
Market Cap	46.67M
EPS	$0 ( 2024-04-02 )
Next earnings date	( $0 ) 2024-06-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.290
ATR14	$0.00700 (0.65%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-15	Patni Rajiv	Buy	54 000	Employee Stock Option (right to buy)
2024-02-15	Patni Rajiv	Buy	0
2024-02-01	Ryan Charles S.	Buy	145 000	Employee Stock Option (right to buy)
2024-02-01	Hannah Brendan	Buy	600 000	Employee Stock Option (right to buy)
2024-02-01	Thye Dirk	Buy	1 500 000	Employee Stock Option (right to buy)

INSIDER POWER
90.02
Last 72 transactions
Buy: 5 607 188 \| Sell: 249 899

Volume Correlation

Long: 0.04 (neutral)

Short: -0.88 (strong negative)

Signal:(48.334) Neutral

Quince Therapeutics, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Quince Therapeutics, Inc. Correlation - Currency/Commodity

-0.20
( neutral )

-0.55
( weak negative )

0.00
( neutral )

-0.52
( weak negative )

-0.60
( weak negative )

0.22
( neutral )

Quince Therapeutics, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-322 000 (0.00 %)
EPS:	$-0.840

FY	2023
Revenue:	$0
Gross Profit:	$-322 000 (0.00 %)
EPS:	$-0.840

FY	2022
Revenue:	$0
Gross Profit:	$-175 000 (0.00 %)
EPS:	$-1.540

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-3.02

Financial Reports:

No articles found.

Quince Therapeutics, Inc.

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.